Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 11101524 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Takekawa M, et al. (2000) p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 19, 6517-26 11101524
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T180-p - P38A (human) ▲
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), COS (fibroblast), HeLa (cervical), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
PHOSPHATASE PPM1D (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPM1D (human) transfection of wild-type enzyme, co-immunoprecipitation, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase

Y182-p - P38A (human) ▲
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), COS (fibroblast), HeLa (cervical), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
 Enzymes shown to modify site in vitro: 
Type Enzyme
PHOSPHATASE PPM1D (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PPM1D (human) transfection of wild-type enzyme, co-immunoprecipitation, phospho-antibody
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase

S33-p - p53 (human) ▲
Orthologous residues
p53 (human): S33‑p, p53 (mouse): P33‑p, p53 iso2 (mouse): P36‑p, p53 (rat): P33‑p, p53 (rabbit): T33‑p, p53 (monkey): S33‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), COS (fibroblast), HeLa (cervical), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) pharmacological activator of upstream enzyme, pharmacological inhibitor of upstream enzyme, phospho-antibody, inhibition of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV PPM1D (human) inhibit treatment-induced increase
SB203580 UV inhibit treatment-induced increase

S46-p - p53 (human) ▲
Orthologous residues
p53 (human): S46‑p, p53 (mouse): L43‑p, p53 iso2 (mouse): L46‑p, p53 (rat): L48‑p, p53 (rabbit): S45‑p, p53 (monkey): S46‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), COS (fibroblast), HeLa (cervical), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase
UV PPM1D (human) inhibit treatment-induced increase
SB203580 UV no effect upon treatment-induced increase

S392-p - p53 (human) ▲
Orthologous residues
p53 (human): S392‑p, p53 (mouse): S386‑p, p53 iso2 (mouse): ‑, p53 (rat): S390‑p, p53 (rabbit): S390‑p, p53 (monkey): S392‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), COS (fibroblast), HeLa (cervical), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human, monkey
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
UV increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.